NIAID participates in or funds many different consortia, clinical trial programs, networks, and research collaborations that help to move science forward. These are listed here, with new ones added all the time. Use the Search by Keyword field to narrow your search.
The Accelerating Medicines Partnership is a public-private collaboration among the National Institutes of Health, pharmaceutical companies, and non-profit organizations.
This program aims to advance novel vaccine adjuvants toward licensure for human use. The program supports the optimization of adjuvant candidates; vaccine formulation and preclinical adjuvant pharmacology, toxicity, and efficacy studies.
The ACTG established and supports the largest Network of expert clinical and translational investigators and therapeutic clinical trials units in the world, including sites in resource-limited countries. These investigators and units serve as the major resource for HIV/AIDS research, treatment, care, and training/education in their communities.
The AADCRC program is the cornerstone of NIAID efforts to promote multidisciplinary basic and clinical research on the immunological basis, pathobiology, diagnosis, treatment, and prevention of asthma and allergic diseases.
The Atopic Dermatitis Research Network is a consortium of academic medical centers that conduct clinical research studies in an attempt to learn more about skin infections associated with atopic dermatitis.
The ACEs conduct collaborative basic and clinical research on autoimmune diseases. Close interaction between clinicians and basic researchers accelerates the discovery, development, and translation of therapies for autoimmune diseases from the lab to use in the clinic.
The National Biocontainment Laboratories (NBLs) and Regional Biocontainment Laboratories (RBLs) provide BSL4/3/2 and BSL3/2 biocontainment facilities, respectively, for research on biodefense and emerging infectious disease agents.
The Bioinformatics and Computational Biosciences Branch (BCBB) drives innovation in biomedical informatics at the NIAID for global health clinicians and researchers by fostering a pipeline of products, platforms, and solutions.
The Bioinformatics Resource Centers (BRCs) for Infectious Diseases program was initiated in 2004 with the main objective of collecting, archiving, updating, and integrating a variety of research data and providing such information through user friendly interfaces and computational analysis tools to be made freely available to the scientific community.
The Center for Advanced Tissue Imaging (CAT-I) is an NIAID and NCI supported effort involving collaborative studies between experts in the Laboratory of Immune System Biology, DIR, NIAID and investigators in the DIR, NIAID and CCR, NCI.
CHAVI-ID are two consortiums established by NIAID to undertake the immunologic research required to tackle the major scientific obstacles in the development of an effective HIV vaccine. The two seven-year awards were made in 2012, one to Duke University and a second to The Scripps Research Institute.
CIDI is a partnership between NIAID and Radiology and Imaging Sciences at the National Institutes of Health Clinical Center. It was established to perform basic science, translational, and clinical research on the imaging features of infectious disease.
The Centers for AIDS Research (CFAR) program at the National Institutes of Health provides administrative and shared research support to synergistically enhance and coordinate high quality AIDS research projects. CFARs accomplish this through core facilities that provide expertise, resources, and services not otherwise readily obtained through more traditional funding mechanisms.
The National Institute of Allergy and Infectious Diseases (NIAID) Centers of Excellence for Influenza Research and Surveillance (CEIRS) program is an integrated network of centers designed to bring together multidisciplinary teams of researchers that perform surveillance related research integrated with research on host immune response, viral pathogenesis, and the factors that control the emerg
In 2014, NIAID established the Centers of Excellence for Translational Research (CETR) program. Supported translational activities will range from very early discovery-based efforts to late-stage preclinical development.
The Clinical Islet Transplantation Consortium is a network of clinical centers and a data coordinating center established in 2004 to conduct studies of islet transplantation in patients with type 1 diabetes.
The Clinical Trials in Organ Transplantation (CTOT) program is an investigative consortium that conducts clinical and associated mechanistic studies to improve outcomes for transplant recipients.
The Clinical Trials in Organ Transplantation in Children (CTOT-C) program focuses on the specific challenges associated with pediatric organ transplantation. This program is a continuation of the first NIAID pediatric transplantation clinical trial consortium, the Cooperative Clinical Trials in Pediatric Transplantation program.
Community Partners (CP) works to promote effective representation of the many US-based and international communities in which the NIH-funded HIV Clinical Trials Networks conduct research.
The Consortium of Food Allergy Research (CoFAR) was established in fiscal year (FY) 2005 to support clinical research on food allergy. It was renewed in FY 2010 to continue several promising clinical studies from the original consortium and expanded to include research on the genetic causes underlying food allergy and the mechanisms of food allergy-associated eosinophilic esophagitis.
The long-term goal of the Cooperative Centers on Human Immunology (CCHI) program is the translation of immunology research into clinical applications in humans in the area of infectious disease.
The purpose of the Creative and Novel Ideas in Research (CNIHR) Program is to create a mechanism via the established Centers for AIDS Research (CFARs) to fund developmental projects to bring insight and new ideas from early-stage investigators, some of whom will have expertise in other disciplines, to the HIV/AIDS field of study.
The Division of AIDS (DAIDS) maintains contracts that can potentially provide limited pre-clinical services including manufacturing, analytical chemistry, preclinical pharmacology and toxicology resources to investigators who are working on the development of therapeutics targeting HIV/AIDS and AIDS-related opportunistic infections, including TB.
The Division of AIDS (DAIDS) offers a unique venture to enable, facilitate, operationalize and translate vaccine developers’ concepts into current good manufacturing practice (cGMP)-manufactured, vialed products for clinical trials.